Home > Investigation and Products > Patents
Patents
| Code | Description | Priority |
|---|---|---|
| 98002 | Interferon alfa 5 use as antiviral for hepatitis C treatment | Sol. ES981003 (3/5/1998) |
| 98003 | Peptide inhibitors of TGF beta 1 | Sol. ES9802465 (24/11/1998) |
| 01008 | Use of Cardiotrophine (CT-1) for the treatment of human liver diseases | Sol. ES200102120 (21/9/2001) |
| 02007 | Peptides Inhibitors of TGF-beta 1 (II) | Sol. ES200302020 (22/8/2003) |
| 03001 | New method for thrombosis risk evaluation by measuring e PCR auto-antibody in plasma | Sol. ES200400269 (06/02/2004) |
| 03004 | Hybrid virus (Adenovirus-alfa/ Semliki Forest) to administer and express therapeutics genes in tumour cells | Sol. ES200401219 (20/05/2004) |
| 04005 | Use of anfirreguline as acute liver protectant agent | Sol. ES200401776 (20/07/2004) |
| 04011 | Oxidised Apo A1 as early markers of Hepatocellular carcinoma | Sol. ES200402989 (16/12/2004) |
| 04007 | New soluble ePCR protein as trombotic marker and potential therapeutic agent | Sol. ES 200500623 (17/03/2005) |
| 04016 | 5'-metiltioadenosina (MTA) in the prevention and treatment of autoimmune diseases | PCT/ES 2005/000139 (17/03/2005) |
| 05008 | Use of cardiotrofina-1 (CT-1) and alfa interferon (IFNa) for combined treatment in viral diseases | Sol. ES200501468 (16/06/2005) |
| 05012 | Fibrosis markers in urine | Sol. ES200501611 (01/07/2005) |
| 04018 | Use of EDA as immune-modulator agent | Sol. ES200501412 (13/06/2005) |
| 05013 | A selection of hepatocellular carcinoma markers | Sol. ES200502369 (29/09/2005) |
| 05009 | Immune-stimulatory combination for hepatitis C prevention | Sol. ES200601563 (09/06/2006) |
| 05030 | Use of peptides inhibitor of TGF-beta1 as a immune response modulator | PCT/ES 2005/000569 (24/10/2005) |
| 06016 iIL10 | IL-10 inhibitors peptides (iIL-10) | Sol. ES200700806 (27/03/2007 |
| 06024 iFoxp3 |
Escurfine inhibitors peptides (i Fox p3) | Sol. ES200703052 (19/11/2007); PCT/ ES2008000716 |
| 06031 MMP10.coag | Metalloproteinase 10 as adjuvant for trombolitic treatment (MMP10) | Sol. ES200700501 (26/02/2007) |
| 07014 aMMP10 Blood |
Metalloproteinase 10 Inhibitors as anti-fibrinolitic treatment (iMMP10) | Sol. ES200701786 (26/06/2007) |
| 07016 TGFb1-MMPs |
Metalloproteinase in combination with iTGF beta for metastasis treatment (MMPs+iTGFbeta-1) | Sol. ES200702309 (20/08/2007) |
| 05033 PPARa CPH |
Inhibitors of PPAR alfa truncated for heart failure prevention in hypertension (iPPAR truncated) | Sol. ES200702625 (05/10/2007) |
| 07005 IFN. CD137 | Association of alfa interferon to 4-1BB agonist antibodies for antitumoral treatment (alfa IFN+4-1BB agonist) | Sol. ES200702961 (7/11/2007; Sol. PCT/ ES2008000693 |
| 07027 IL12.iTGFb1 | iTGF beta 1 as adjuvant for the antitumoral effect of IL 12 induced expression (IL 12+iTGF beta 1) | Sol. ES200800417 (15/02/2008) |
| 07038 Packsis | System for packaging of high-capacity adenovirus | Sol. ES200801682 (04/06/2008) |
| 08005 ApoA1.vec | Conjugates for the adminstration of biologically active compounds | Sol. ES200801796 (13/06/2008) |
| 07017 aWnt.HCC | Anti-angiogenic agents | Sol. ES200802023 (02/07/2008) |
| 08014 RHOB.NSCLC | Novel biomarker as a therapeutic target in lung cancer | Sol. ES200802503 (28/08/2008) |
| 08007 PSM.vac | Use of phenol soluble modulins for the development of vaccines | Sol. ES200803441 (03/12/2008) |
| 08018 IFNa.OSM.cáncer | Oncostatin M as an enhancer of the immunoestimulatory activity of human epithelial cells | Sol. ES200802835 (07/10/2008) |
| 08004 iA2a. Ad.Rc | Compounds for the treatment of auricular fibrillation | Sol. ES200502545 (14/10/2005) |
| 05024 iTGFb1.FTopica | Método para el tratamiento de fibrosis de piel y composiciones aceptables para su tratamiento | Sol. US11/365,764 (01/03/2006) |
| 08016 P144 CD | Formulaciones farmacéuticas de péptidos inhibidores de TGFb1 | Sol. ES200900319 (05/02/2009) |
© Digna Biotech ˇ Legal Information
Top